Prerequisites for the pharmaceutical industry to develop and commercialise helminths and helminth-derived product therapy

International Journal for Parasitology

Volumn 43, Issue 3-4, 2013, Pages 319-325

  Tilp, Cornelia ^a   Kapur, Vishal ^a   Loging, Will ^b   Erb, Klaus J ^a  

^a BOEHRINGER INGELHEIM PHARMA GMBH AND CO KG   (Germany)

^b BOEHRINGER INGELHEIM PHARMACEUTICALS INC   (United States)

Author keywords

Allergic diseases; Autoimmune diseases; Helminth therapy; Helminth derived product therapy; Immune regulation; Pharmaceutical industry

Indexed keywords

PARASITE ANTIGEN;

ALLERGY; DISEASE TREATMENT; DRUG DEVELOPMENT; IMMUNE SYSTEM; PARASITIC DISEASE; PHARMACEUTICAL INDUSTRY; PRODUCT DEVELOPMENT;

ALLERGY; ASCARIS LUMBRICOIDES; ATOPY; AUTOIMMUNE DISEASE; CLINICAL TRIAL (TOPIC); COMMERCIAL PHENOMENA; DISEASE MODEL; DRUG INDUSTRY; DRUG MARKETING; DRUG RESEARCH; DRUG SAFETY; ENTERITIS; FILARIA; FINANCIAL MANAGEMENT; HUMAN; IMMUNOREGULATION; INVESTMENT; LOEFFLER PNEUMONIA; MEDICAL INFORMATION; METHODOLOGY; NECATOR AMERICANUS; NONHUMAN; PATENT; PERSONALIZED MEDICINE; QUALITY CONTROL; REPRODUCIBILITY; REVIEW; THERAPY WITH HELMINTHS; TRANSLATIONAL RESEARCH; TREATMENT OUTCOME; TRICHURIS SUIS; TRICHURIS TRICHIURA;

ANIMALS; DRUG INDUSTRY; DRUG THERAPY; HELMINTHS; HUMANS; MICE; THERAPY WITH HELMINTHS;

ANIMALIA; MUS; NECATOR AMERICANUS; TRICHURIS SUIS; VERMES;

EID: 84873719095     PISSN: 00207519     EISSN: 18790135     Source Type: Journal    
DOI: 10.1016/j.ijpara.2012.12.003     Document Type: Review

References (44)

1. Allam J.P., Peng W.M., Appel T., Wenghoefer M., Niederhagen B., Bieber T., Bergé S., Novak N. Toll-like receptor 4 ligation enforces tolerogenic properties of oral mucosal langerhans cells. J. Allergy Clin. Immunol. 2008, 121:368-374.
2. Aronson J.K. Rare diseases and orphan drugs. Br. J. Clin. Pharmacol. 2006, 61:243-245.
3. Arrowsmith J. Trial watch: phase II failures: 2008-2010. Nat. Rev. Drug Discov. 2011, 10:328-329.
4. Berth-Jones J., Arkwright P.D., Marasovic D., Savani N., Aldridge C.R., Leech S.N., Morgan C., Clark S.M., Ogilvie S., Chopra S. Killed Mycobacterium vaccae suspension in children with moderate-to-severe atopic dermatitis: a randomized, double-blind, placebo-controlled trial. Clin. Exp. Allergy 2006, 36:1115-1121.
5. Brothers S., Asher M.I., Jaksic M., Stewart A.W. Effect of a Mycobacterium vaccae derivative on paediatric atopic dermatitis: a randomized, controlled trial. Clin. Exp. Dermatol. 2009, 34:770-775.
6. Casale T.B., Stokes J.R. Future forms of immunotherapy. J. Allergy Clin. Immunol. 2011, 127:8-15.
7. Cooke A. Parasitic worms and inflammatory disease. Curr. Opin. Rheumatol. 2012, 24:394-400.
8. Cooper P.J. Interactions between helminth parasites and allergy. Curr. Opin. Allergy Clin. Immunol. 2009, 9:29.
9. Duechs M.J., Hahn C., Benediktus E., Werner-Klein M., Braun A., Hoymann H.G., Gantner F., Erb K.J. TLR agonist mediated suppression of allergic responses is associated with increased innate inflammation in the airways. Pulm. Pharmacol. Ther. 2011, 24:203-214.
10. Elliott D.E., Weinstock J.V. Helminth-host immunological interactions: prevention and control of immune-mediated diseases. Ann. N.Y. Acad. Sci. 2012, 1247:83-96.
11. Erb K.J. Can helminths or helminth-derived products be used in humans to prevent or treat allergic diseases?. Trends Immunol. 2009, 30:75-82.
12. Erb K.J., Holloway J.W., Sobeck A., Moll H., Le Gros G. Infection of mice with Mycobacterium bovis-Bacillus Calmette-Guerin (BCG) suppresses allergen-induced airway eosinophilia. J. Exp. Med. 1998, 187:561-569.
13. Facciabene A., Motz G.T., Coukos G. T-Regulatory cells: key players in tumor immune escape and angiogenesis. Cancer Res. 2012, 72:2162-2171.
14. Flohr C., Quinnell R.J., Britton J. Do helminth parasites protect against atopy and allergic disease?. Clin. Exp. Allergy 2009, 39:20-32.
15. Fonseca D.E., Kline J.N. Use of CpG oligonucleotides in treatment of asthma and allergic disease. Adv. Drug Deliv. Rev. 2009, 61:256-262.
16. Harnett M.M., Melendez A.J., Harnett W. The therapeutic potential of the filarial nematode-derived immunodulator, ES-62 in inflammatory disease. Clin. Exp. Immunol. 2010, 159:256-267.
17. Hartmann S., Schnoeller C., Dahten A., Avagyan A., Rausch S., Lendner M., Bocian C., Pillai S., Loddenkemper C., Lucius R. Gastrointestinal nematode infection interferes with experimental allergic airway inflammation but not atopic dermatitis. Clin. Exp. Allergy 2009, 39:1585-1596.
18. Ince M.N., Elliott D.E., Setiawan T., Metwali A., Blum A., Chen H., Urban J.F., Flavell R.A., Weinstock J.V. Role of T cell TGF-β signaling in intestinal cytokine responses and helminthic immune modulation. Eur. J. Immunol. 2009, 39:1870-1878.
19. Kamradt T., Göggel R., Erb K.J. Induction, exacerbation and inhibition of allergic and autoimmune diseases by infection. Trends Immunol. 2005, 26:260-267.
20. Krieg A.M. CpG still rocks! Update on an accidental drug. Nucleic Acid Ther. 2012, 22:77-89.
21. Kuijk L.M., Klaver E.J., Kooij G., van der Pol S., Heijnen P., Bruijns S., Kringel H., Pinelli E., Kraal G., de Vries H.E. Soluble helminth products suppress clinical signs in murine experimental autoimmune encephalomyelitis and differentially modulate human dendritic cell activation. Mol. Immunol. 2012, 51:210-218.
22. Lima C., Perini A., Garcia M.L.B., Martins M.A., Teixeira M.M., Macedo M.S. Eosinophilic inflammation and airway hyper-responsiveness are profoundly inhibited by a helminth (Ascaris suum) extract in a murine model of asthma. Clin. Exp. Allergy 2002, 32:1659-1666.
23. Maizels R., Yazdanbakhsh M. Immune regulation by helminth parasites: cellular and molecular mechanisms. Nat. Rev. Immunol. 2003, 3:733-744.
24. Maizels R.M., Pearce E.J., Artis D., Yazdanbakhsh M., Wynn T.A. Regulation of pathogenesis and immunity in helminth infections. J. Exp. Med. 2009, 206:2059-2066.
25. Marshall H.D., Urban S.L., Welsh R.M. Virus-induced transient immune suppression and the inhibition of T cell proliferation by type I interferon. Sci. STKE 2011, 85:5929.
26. Mohapatra S.S., Qazi M., Hellermann G. Immunotherapy for allergies and asthma: present and future. Curr. Opin. Pharmacol. 2010, 10:276-288.
27. Mortimer K., Brown A., Feary J., Jagger C., Lewis S., Antoniak M., Pritchard D., Britton J. Dose-ranging study for trials of therapeutic infection with Necator americanus in humans. Am. J. Trop. Med. Hyg. 2006, 75:914-920.
28. Pohlers D., Brenmoehl J., Löffler I., Müller C.K., Leipner C., Schultze-Mosgau S., Stallmach A., Kinne R.W., Wolf G. TGF-β and fibrosis in different organs - molecular pathway imprints. Biochim. Biophys. Acta 2009, 1792:746-756.
29. Prinz F., Schlange T., Asadullah K. Believe it or not: how much can we rely on published data on potential drug targets?. Nat. Rev. Drug Discov. 2011, 10:712.
30. Pritchard D.I., Blount D.G., Schmid-Grendelmeier P., Till S.J. Parasitic worm therapy for allergy: is it incongruous or avant-garde medicine?. Clin. Exp. Allergy 2012, 42:505-512.
31. Reddy A., Fried B. An update on the use of helminths to treat Crohn's and other autoimmune diseases. Parasitol. Res. 2009, 104:217-221.
32. Ruyssers N.E., De Winter B.Y., De Man J.G., Loukas A., Herman A.G., Pelckmans P.A., Moreels T.G. Worms and the treatment of inflammatory bowel disease: are molecules the answer?. Clin. Dev. Immunol. 2008, 2008:2.
33. Schreiber R.D., Old L.J., Smyth M.J. Cancer immunoediting: integrating immunity's roles in cancer suppression and promotion. Sci. STKE 2011, 331:1565.
34. Steenhuis T.J., Van Aalderen W.M.C., Bloksma N., Nijkamp F.P., Van Der Laag J., Van Loveren H., Rijkers G.T., Kuis W., Hoekstra M.O. Bacille-Calmette-Guerin vaccination and the development of allergic disease in children: a randomized, prospective, single-blind study. Clin. Exp. Allergy 2008, 38:79-85.
35. Summers R.W., Elliott D.E., Qadir K., Urban J.F., Thompson R., Weinstock J.V. Trichuris suis seems to be safe and possibly effective in the treatment of inflammatory bowel disease. Am. J. Gastroenterol. 2003, 98:2034-2041.
36. Summers R.W., Elliott D.E., Urban J.F., Thompson R., Weinstock J.V. Trichuris suis therapy in Crohn's disease. Gut 2005, 54:87-90.
37. Thompson B.S., Chilton P.M., Ward J.R., Evans J.T., Mitchell T.C. The low-toxicity versions of LPS, MPL-adjuvant and RC529, are efficient adjuvants for CD4+ T cells. J. Leukoc. Biol. 2005, 78:1273-1280.
38. Trujillo-Vargas C.M., Werner-Klein M., Wohlleben G., Polte T., Hansen G., Ehlers S., Erb K.J. Helminth-derived products inhibit the development of allergic responses in mice. Am. J. Respir. Crit. Care Med. 2007, 175:336-344.
39. van der Worp H.B., Howells D.W., Sena E.S., Porritt M.J., Rewell S., O'Collins V., Macleod M.R. Can animal models of disease reliably inform human studies?. PLoS Med. 2010, e7:e1000245.
40. Vollmer J., Krieg A.M. Immunotherapeutic applications of CpG oligodeoxynucleotide TLR9 agonists. Adv. Drug Deliv. Rev. 2009, 61:195-204.
41. Wilson M.S., Taylor M.D., Balic A., Finney C.A.M., Lamb J.R., Maizels R.M. Suppression of allergic airway inflammation by helminth-induced regulatory T cells. J. Exp. Med. 2005, 202:1199-1212.
42. Wohlleben G., Trujillo C., Muller J., Ritze Y., Grunewald S., Tatsch U., Erb K.J. Helminth infection modulates the development of allergen-induced airway inflammation. Int. Immunol. 2004, 16:585-596.
43. Zaccone P., Fehervari Z., Phillips J.M., Dunne D.W., Cooke A. Parasitic worms and inflammatory diseases. Parasite Immunol. 2006, 28:515-523.
44. Zuberbier T., Bachert C., Bousquet P.J., Passalacqua G., Walter Canonica G., Merk H., Worm M., Wahn U., Bousquet J. GA2LEN/EAACI pocket guide for allergen-specific immunotherapy for allergic rhinitis and asthma. Allergy 2010, 65:1525-1530.